October 24, 2018 / 6:53 PM / 22 days ago

BRIEF-Genentech Announces FDA Approval Of Xofluza For Influenza

Oct 24 (Reuters) - Roche Holding AG:

* GENENTECH ANNOUNCES FDA APPROVAL OF XOFLUZA (BALOXAVIR MARBOXIL) FOR INFLUENZA

* GENENTECH SAYS FDA APPROVED XOFLUZA (BALOXAVIR MARBOXIL) FOR TREATMENT OF ACUTE, UNCOMPLICATED INFLUENZA, OR FLU, IN PEOPLE 12 YEARS OF AGE AND OLDER

* GENENTECH - ROCHE HOLDS WORLDWIDE RIGHTS TO XOFLUZA EXCLUDING JAPAN AND TAIWAN, WHICH WILL BE RETAINED EXCLUSIVELY BY SHIONOGI & CO., LTD Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below